Hosted on MSN2h
Why Eli Lilly’s CEO says failing faster is essential to the company’s success
On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...
The Motley Fool8h
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
Right now, Eli Lilly dominates the weight loss industry thanks to its dual agonists Mounjaro and Zepbound. Viking ...
Indianapolis Recorder22h
Eli Lilly CEO named Life Sciences Champion of the Year
BioCrossroads has named Eli Lilly CEO, Dave Ricks, the recipient of the 2024 August M. Watanabe Life Sciences Champion of the ...
BioSpace2d
Leqembi, Kisunla and Beyond: The Next Wave of Alzheimer’s at CTAD 2024
With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...
alzheimersnewstoday5d
Modified Kisunla dosing shown to lower risk of ARIA-E in Alzheimer’s
Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.
Ibj.com5d
Lilly CEO Dave Ricks named Watanabe Award winner
Ricks is being recognized for his contributions to Indiana’s life sciences sector and his global impact on health care ...
BizTimes5d
Eli Lilly buys another 31 acres in Kenosha County
Indianapolis-based pharmaceutical giant Eli Lilly and Company has purchased 30.9 acres of vacant land to the north and to the ...
BioWorld6d
Lilly bid wilts as others forge on with PD-1 in RA
Eli Lilly and Co.’s chief scientific officer, Daniel Skovronsky, called peresolimab, the PD-1 agonist previously in the works by the firm for rheumatoid arthritis (RA), a “really interesting mechanism ...